What are the recommended doses, benefits, and drawbacks of the induction agents (etomidate, ketamine, propofol, and midazolam) used for rapid sequence intubation (RSI)?

Induction Agent Selection for RSI in Critically Ill Adults

All four induction agents (etomidate, ketamine, propofol, midazolam) show no significant difference in mortality outcomes, but their hemodynamic profiles differ substantially—select based on the patient's hemodynamic status and specific clinical context rather than mortality concerns. 1

Recommended Dosing

Etomidate

• Standard dose: 0.2-0.3 mg/kg IV
• Reduced dose: 0.15 mg/kg in hemodynamically compromised patients 1

Ketamine

• Standard dose: 1-2 mg/kg IV 1
• Most studies used this range consistently

Propofol

• Induction dose: 1.5-2 mg/kg IV (unpremedicated patients <55 years)
• Reduced dose: 1-1.5 mg/kg in elderly or hemodynamically unstable patients 2
• Can be as low as 0.2-0.25 mg/kg in debilitated/ASA III-IV patients

Midazolam

• Induction dose: 0.2-0.35 mg/kg IV 3
• Elderly/debilitated: 0.15-0.2 mg/kg over 2+ minutes
• Conscious sedation only: 1-1.5 mg titrated slowly (not typically used for RSI induction)

Advantages and Disadvantages by Agent

Etomidate

Advantages:

• Most favorable hemodynamic profile among single agents 1
• Quick onset and short duration
• Minimal effect on blood pressure in most patients
• No difference in mortality versus other agents (moderate quality evidence) 1

Disadvantages:

• Inhibits 11-beta-hydroxylase, causing adrenal suppression 1
• Significantly higher incidence of adrenal insufficiency (OR 2.43) 4
• May require more vasopressor support in some studies 4
• Concerns about adrenal enzyme inhibition effects on critically ill patients

Ketamine

Advantages:

• Quick onset, short duration 1
• Preserves respiratory drive 1
• Sympathomimetic properties maintain blood pressure in most patients 1
• Lowest rates of respiratory depression (apnea, hypoxia) among all agents 5
• Less adrenal suppression than etomidate (OR 0.54) 6
• Decreased need for initiation of continuous vasopressor infusions versus etomidate (RR 0.75) 6

Disadvantages:

• Risk of hypotension and cardiac arrest in patients with depleted catecholamine stores 1
• Higher peri-intubation hemodynamic instability (RR 1.29-1.30) 6, 7
• More post-induction hypotension than etomidate in some studies 7
• Contraindicated in elevated intracranial pressure scenarios (traditional teaching, though debated)

Propofol

Advantages:

• Quick onset and short duration 1
• Smooth induction
• When combined with ketamine, significantly reduces adverse events including hypotension, vomiting, intubation difficulty, bradycardia, and laryngospasm 5

Disadvantages:

• Most profound effect on blood pressure of all agents 1
• Highest incidence of hypotension when used alone 5
• Second highest rate of hypoxia after midazolam 5
• Significantly limits use in critically ill, hemodynamically unstable patients 1
• Risk of propofol infusion syndrome with prolonged use
• Requires dose reduction in elderly, debilitated, or fluid-depleted patients 2

Midazolam

Advantages:

• Familiar agent with predictable effects
• Provides amnesia

Disadvantages:

• Longer onset of action compared to etomidate and ketamine 1
• Potent venodilator at RSI doses 1
• Least desirable for RSI among the four agents 1
• Highest rate of hypoxia among evaluated agents 5
• Requires very slow titration in elderly (over 2+ minutes) 3
• Not recommended as first-line for RSI in critically ill patients

Clinical Decision Algorithm

For hemodynamically stable patients:

• Any agent acceptable; etomidate or ketamine preferred for rapid, reliable induction
• Propofol acceptable if blood pressure robust

For hemodynamically unstable/shock patients:

• First choice: Etomidate (best hemodynamic stability) 1
• Alternative: Ketamine (if catecholamine stores likely intact, younger patient) 1
• Avoid: Propofol (most hypotensive) 1, 5
• Avoid: Midazolam (venodilator, slow onset) 1

For trauma/sepsis with concern for adrenal function:

• Consider ketamine over etomidate to avoid adrenal suppression 4, 6
• Accept slightly higher risk of peri-intubation hemodynamic instability with ketamine

Combination approach (when available):

• Propofol-ketamine combination offers superior hemodynamic stability compared to either agent alone 5, 8
• Reduces hypotension, vomiting, and other adverse events
• Consider in patients where single-agent risks are concerning

Critical Pitfalls to Avoid

1. Do not omit sedation when using paralytics—awareness during paralysis occurs in 2.6% of ED intubations and is ethically unacceptable 1

2. Do not assume dose reduction prevents hypotension—recent large registry data shows no association between weight-based sedative dose and post-intubation hypotension for either etomidate or ketamine 9

3. Do not use midazolam as first-line for RSI—slower onset and potent venodilation make it least suitable 1

4. Do not use propofol in shock states—most profound hypotensive effect limits utility in critically ill patients 1, 5

5. Recognize ketamine's limitations in catecholamine-depleted states—prolonged shock, severe sepsis, or chronic critical illness may predispose to paradoxical hypotension 1

6. Prepare for post-intubation hypotension regardless of agent choice—peri-intubation hypotension is common (16-29% incidence) and associated with worse outcomes including organ dysfunction, prolonged mechanical ventilation, and increased mortality 1

Key Evidence Nuances

The 2023 Society of Critical Care Medicine guidelines provide a conditional recommendation that there is no difference between etomidate and other agents for mortality or hypotension (moderate quality evidence) 1. However, this represents equipoise in outcomes, not equivalence in mechanism—the agents have distinctly different hemodynamic profiles that matter for individual patient selection.

Recent meta-analyses show conflicting results on hemodynamic stability: ketamine increases peri-intubation instability but decreases need for continuous vasopressor infusions 6, suggesting different timing and types of hemodynamic effects. The most recent 2025 meta-analyses confirm no mortality difference but highlight ketamine's adrenal-sparing effects 4, 6, 7.

The evidence supports agent selection based on hemodynamic profile and specific patient factors rather than mortality concerns, as all agents appear equivalent for survival outcomes when used appropriately.